Open-label, single-dose, multi-center, multi-national pivotal study of AMT 061 in the adult patients with severe and moderately severe hemophilia B

Trial Profile

Open-label, single-dose, multi-center, multi-national pivotal study of AMT 061 in the adult patients with severe and moderately severe hemophilia B

Planning
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs AMT 061 (Primary)
  • Indications Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Sponsors uniQure
  • Most Recent Events

    • 31 Oct 2017 According to an uniQure media release, this trial is expected to begin in 2018.
    • 31 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top